Please login to the form below

Not currently logged in

Amgen posts decrease in earnings

Amgen's second quarter financial results hit by US healthcare reform fees

US pharmaceutical company Amgen has reported a 3 per cent decrease in net income for the second quarter of 2011 to $1.3bn.

The company reported a 4 per cent increase in sales during the three month period to $3.96bn.

Kevin Sharer, chairman and CEO, said: "Our products recorded a strong 8 per cent growth during the quarter. Our business has momentum and we expect to be at the upper end of our revenue and EPS [earnings per share] guidance."

Amgen said that its R&D expenses increased by 26 per cent in the quarter to $808m, reflecting the costs associated with late stage clinical programmes, it said. Meanwhile its selling, general and administrative expenses increased by 15 per cent in the second quarter to $1.1bn driven by the US Healthcare Reform Federal Exercise Fee of $47m.

1st August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Londonvelophobia (fear of cycling in London) – debunked
How Helpful are Simple Health Messages?
So, we’ve arrived. Our work has stepped beyond multichannel to omnichannel. We can be and in fact are everywhere, all the time. We are omni-present. We are God. Or are...